Can Allergy Drops Cause Anaphylaxis?

According to the published medical literature, no deaths attributable to sublingual immunotherapy have been reported worldwide. This stands in contrast to allergy shots, where rare fatal reactions have historically been documented. The strong safety record of allergy drops is one of the main reasons they can be taken at home rather than requiring a clinical setting for every dose. That said, no medical treatment is completely without risk, and serious reactions, while extraordinarily rare, are theoretically possible. This is why providers prescribe an epinephrine auto-injector and review warning signs with patients. If you ever experience trouble breathing or throat tightness after a dose, treat it as an emergency.

An epinephrine auto-injector is prescribed as a sensible precaution, not because a severe reaction is expected. Because immunotherapy intentionally exposes you to your allergens, the standard of care is to have rescue epinephrine on hand in case a rare systemic reaction occurs. Think of it like a smoke detector: you hope never to use it, but having it provides a critical safety margin. Anaphylaxis from sublingual immunotherapy is estimated at roughly one event per 100 million doses, so the auto-injector will almost certainly never be needed. Your provider will show you how and when to use it and will review the warning signs that would prompt its use.

The first dose carries slightly more uncertainty than later doses simply because it is your body's first exposure to the prescribed extract, which is why many providers observe the initial dose. Even so, serious reactions on the first dose are very uncommon. Most people experience nothing more than mild itching or tingling in the mouth, which tends to lessen with continued use. After the first dose, the body generally tolerates the daily routine well. If you do have a notable reaction at any point, contact your provider before continuing, and seek emergency care for any signs of difficulty breathing, throat tightness, or fainting.

A local reaction is confined to the area where the drops are placed, typically itching or mild swelling in the mouth, throat, or ears. These are common, expected, and usually harmless, affecting roughly 40 percent of patients early in treatment. Anaphylaxis is entirely different: it is a rapid, whole-body reaction involving multiple systems at once, such as difficulty breathing, throat tightness, a drop in blood pressure, dizziness, or fainting. Anaphylaxis is exceptionally rare with sublingual immunotherapy. The key distinction is that local reactions stay in the mouth and resolve on their own, while anaphylaxis spreads and worsens quickly and requires emergency epinephrine and a 911 call.

The difference comes down to how the allergen enters the body. With allergy shots, the extract is injected under the skin, where it can be absorbed relatively quickly and reach the bloodstream, which is associated with a higher risk of systemic reactions including, rarely, anaphylaxis. With allergy drops, the allergen is held under the tongue and absorbed slowly through the lining of the mouth, where specialized immune cells help promote tolerance rather than triggering a rapid whole-body response. This slower, more localized exposure is a key reason sublingual immunotherapy carries a lower risk of systemic reactions than shots and can be taken at home. Both approaches still warrant standard precautions such as a prescribed epinephrine auto-injector.